Download PDF
Pharmacopsychiatry 2001; 34(6): 242-250
DOI: 10.1055/s-2001-18036
Review
© Georg Thieme Verlag Stuttgart · New York

Oxcarbazepine in Affective and Schizoaffective Disorders

D. E. Dietrich, S. Kropp, H. M. Emrich
  • Department of Clinical Psychiatry and Psychotherapy, Hannover Medical School, Germany
Further Information

Publication History

Publication Date:
26 October 2001 (online)

Also available at
    Permissions and Reprints

Anticonvulsants have been successfully used in pharmacopsychiatry after their therapeutic value in affective and schizoaffective disorders had been documented in several clinical trials. As the authorities in several countries registered newer anticonvulsants with fewer side effects, their therapeutic value in psychiatric disorders was studied. Clinical studies from the early 80's onward have demonstrated the efficacy of oxcarbazepine (OCBZ), a keto derivative of carbamazepine, in treating mania in affective and schizoaffective disorders. In addition, OCBZ has a distinct pharmacokinetic profile concerning drug-drug interactions compared to carbamazepine and other anticonvulsants. Therefore, the value of OCBZ in the treatment of affective and schizoaffective disorders needs to be evaluated. We reviewed the literature with regard to pharmacokinetic and pharmacodynamic characteristics of OCBZ, drug-drug interactions relevant in pharmacopsychiatry, and the clinical effects of OCBZ in the treatment of patients with affective and schizoaffective disorders. According to the literature, OCBZ is regarded as effective in acute mania and appears to reduce the dosage of neuroleptics required for the treatment of affective and schizoaffective disorders. In addition, it has a preferable pharmacokinetic profile with less severe side effects compared to carbamazepine and neuroleptics. Furthermore, since OCBZ does not interact substantially with the cytochrome P450 enzyme system, co-administration with neuroleptics or antidepressants appears to be well tolerated in affective disorders. However, despite promising effects of OCBZ, few clinical studies have been published in the last 15 years. We conclude that further studies should validate the efficacy of OCBZ in treating mania and evaluate possible pharmacopsychiatric indications as well as limitations for this psychotropic compound.

References

  • 1 Äikiä M, Kälviäinen R, Sivenius J, Halonen T, Riekkinnen P J. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up.  Epilepsy Research. 1992;  1 199-203
    PubMedGoogle Scholar
  • 2 Aggleton J P, Mishkin M. The amygdala: sensory gateway to the emotions. In: Plutchik R, Kellermann H (eds) Emotion: Theory, Research and Experience. Orlando; Academic Press 1986
    Google Scholar
  • 3 Anderman F, Schwabe S, McLean M J, Lloyd P, Baruzzi A. Panel discussion: Part I.  Epilepsia. 1994;  35 (3) S20
    PubMedGoogle Scholar
  • 4 Ballenger J C, Post R M. Carbamazepine in manic-depressive illness: a new treatment.  Am J Psychiatry. 1980;  137 782-790
    CrossrefPubMedGoogle Scholar
  • 5 Bech P, Bolwig T G, Kramp P, Rafaelson O J. The Bech-Rafaelson Mania Scale and the Hamilton Depression Scale: evaluation of homogenity and inter-observer reliability.  Acta Psychiatr Scand. 1979;  59 420-430
    PubMedGoogle Scholar
  • 6 Beijamini V, Skalisz L L, Joca S R, Andreatini R. The effect of oxcarbazepine of behavioural despair and learned helplessness.  Eur J Pharmacol. 1998;  347 (1) 23-27
    CrossrefPubMedGoogle Scholar
  • 7 Beran R G. Cross-reactive skin eruption with both carbamazepine and oxcarbamazepine.  Epilepsia. 1993;  34 163-165
    PubMedGoogle Scholar
  • 8 Bill P A, Vigonius U, Pohlmann A, Guerreiro C AM, Kochen S, Saffer D, Moore A. A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy.  Epilepsy Research. 1997;  27 195-204
    CrossrefPubMedGoogle Scholar
  • 9 Borusiak P, Korn-Merker E, Holert N, Boenigk H E. Hyponatremia induced by oxcarbazepine in children.  Epilepsy Res. 1998;  30 241-246
    CrossrefPubMedGoogle Scholar
  • 10 Bülau P, Paar W D, von Unruh G E. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother.  Eur J Clin Pharmacol. 1988;  34 311-313
    CrossrefPubMedGoogle Scholar
  • 11 Cabrera J F, Mühlbauer H D, Schley J, Stoll K D, Müller-Oerlinghausen B. Long-term randomized clinical trial on oxcarbazepine vs. lithium in bipolar and schizoaffective disorders: preliminary results.  Pharmacopsychiatry. 1986;  19 282-283
    PubMedGoogle Scholar
  • 12 Cabrera J, Albrecht J, Müller-Oerlinghausen B. Kombinierte rezidiv-prophylaktische Behandlung der manisch-depressiven Erkrankung mit Lithium und Carbamazepin oder Oxcarbazepin.  Nervenarzt. 1987;  58 245-249
    PubMedGoogle Scholar
  • 13 Curran H V, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers.  Eur J Clin Pharmacol. 1993;  44 529-533
    CrossrefPubMedGoogle Scholar
  • 14 Christe W, Krämer G, Vigonius U, Pohlmann H, Steinhoff B J, Martin J B, Martin J B, Moore A. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy.  Epilepsy Research. 1997;  26 451-460
    CrossrefPubMedGoogle Scholar
  • 15 Dam M. Practical aspects of oxcarbazepine treatment.  Epilepsia. 1994;  35 (3) S23-S25
    PubMedGoogle Scholar
  • 16 Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy.  Epilepsy Res. 1989;  3 70-76
    CrossrefPubMedGoogle Scholar
  • 17 Davis M. The role of amygdala in fear-potentiated startle: implications for animal models of anxiety.  Trends Pharmacol Sci. 1992;  13 35-41
    CrossrefPubMedGoogle Scholar
  • 18 Dickinson R G, Hooper W D, Dunstan P R, Eadie M J. First dose and steady-state pharmacokinetics of oxcarbazepine in its 10-hydroxy metabolite.  Eur J Clin Pharmacol. 1989;  37 69-74
    PubMedGoogle Scholar
  • 19 Dietrich D E, Emrich H M. The use of anticonvulsants to augment antidepressant medication.  J Clin Psychiatry. 1998;  59 (5) 51-58
    PubMedGoogle Scholar
  • 20 Dunn R T, Frye M S, Kimbrell T A, Denicoff K D, Leverich G S, Post R M. The efficacy and use of anticonvulsants in mood disorders.  Clin Neuropharmacology. 1998;  21 215-235
    PubMedGoogle Scholar
  • 21 Eadie M J, Tyrer J H. Carbamazepine. In: Anticonvulsant therapy-pharmacological basis and practice, 3rd Ed. Oxford; Churchill Livingstone 1989: 142-143
    Google Scholar
  • 22 Emrich H M. Studies with oxcarbazepine (Trileptal) in acute mania.  Intern Clin Psychopharmacol. 1990;  5 (1) 83-88
    PubMedGoogle Scholar
  • 23 Emrich H M. Experience with oxcarbazepine in acute mania. In: Modigh K, Robak OH, Vestergaard P (eds) Whrightson Biomedical Publishing 1994: 29-36
  • 24 Emrich H M, von Zerssen D, Kissling W, Möller H J, Windorfer A. Effect of sodium valproate in mania. The GABA-hypothesis of affective disorders.  Arch Psychiat Nervenkr. 1980;  229 1-16
    CrossrefPubMedGoogle Scholar
  • 25 Emrich H M, Altmann H, Dose M, von Zerssen D. Therapeutic effects of GABA-ergic drugs in affective disorders - A preliminary report.  Pharmacol Biochem Behav. 1983;  19 369-372
    CrossrefPubMedGoogle Scholar
  • 26 Emrich H M, Dose M, von Zerssen D. Action of sodium-valproate and of oxcarbazepine in patients with affective disorders. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam; Excerpta Medica 1984: 45-55
    Google Scholar
  • 27 Emrich H M, Dose M, von Zerssen D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders.  J Affect Disorders. 1985;  8 243-250
    PubMedGoogle Scholar
  • 28 Emrich H M, Dose M, Wolf R. The action of mood-stabilizers in affective disorders: an integrative view as a challenge.  Neuropsychobiology. 1993;  27 158-162
    PubMedGoogle Scholar
  • 29 Fähndrich E. Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. Berlin; Springer 1981
  • 30 Faigle J W, Menge G P. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions.  Behav Neurol. 1990;  3 (1) 21-30
    PubMedGoogle Scholar
  • 31 Fattore C, Cipolla G, Gatti G, Limodo G L, Sturm Y, Bernasconi C, Perucca E. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women.  Epilepsia. 1999;  40 783-787
    PubMedGoogle Scholar
  • 32 Friis M L, Kristensen O, Boas J, Dalby M, Deth S H, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Pedersen J, Andersen D, Jensen P K. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment.  Acta Neurol Scand. 1993;  87 224-227
    PubMedGoogle Scholar
  • 33 Garbutt J C, Loosen P T. Is carbamazepine helpful in paroxysmal behavior disorder?.  Am J Psychiatry. 1983;  140 1363-1364
    PubMedGoogle Scholar
  • 34 Garcia-Borreguero D, Raptis C, Weber M M, Dose M, Bremer D, Emrich H M. Anticonvulsants as adjuncts for the neuroleptic treament of schizophrenic psychoses: a clinical study with beclamide.  Acta Psychiat Scand. 1989;  81 162-167
    PubMedGoogle Scholar
  • 35 Gatzonis S D, Georgaculias N, Singounas E, Jenkins A, Stamboulis E, Siafakas A. Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation.  Neurology. 1999;  52 1918-1919
    PubMedGoogle Scholar
  • 36 Grant S M, Faulds D. Oxcarbazepine - A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.  Drugs. 1992;  43 873-888
    CrossrefPubMedGoogle Scholar
  • 37 Greil W, Ludwig-Mayerhofer W, Erazo N, Schochlin C, Schmidt S, Engel R R, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf G A, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomized study.  J Affect Disord. 1997a;  43 151-161
    CrossrefPubMedGoogle Scholar
  • 38 Greil W, Ludwig-Mayerhofer W, Erazo N, Engel R R, Czernik A, Giedke H, Müller-Oerlinghausen B, Osterheider M, Rudolf G A, Sauer H, Tegeler J, Wetterling T. Lithium versus carbamazepine in the maintenance treatment of schizoaffective disorder - a randomized study.  Eur Arch Psychiatry Clin Neurosci. 1997b;  247 42-50
    PubMedGoogle Scholar
  • 39 Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.  J Clin Psychopharmacol. 1998;  18 455-460
    CrossrefPubMedGoogle Scholar
  • 40 Hakaola H PA, Laulumaa V A. Carbamazepine in violent schizophrenia. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affecive disorders. Amsterdam; Exerpta Medica 1984: 204-207
    Google Scholar
  • 41 Houtkooper M A, Lammertsma A, Meyer J W, Goedhart D M, Meinardi H, van Oorschot C A, Blom G F, Hoppener R J, Hulsman J A. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?.  Epilepsia. 1987;  28 (6) 693-698
    PubMedGoogle Scholar
  • 42 Isojarvi J I, Pakarinen A J, Myllyla V V. Basic haematological parameters, serum gamma-glutamyl-transferase activity, and erythrocyte folate and serum vitamin B 12 levels during carbamazepine and oxcarbazepine therapy.  Seizure. 1997;  6 207-211
    CrossrefPubMedGoogle Scholar
  • 43 Joca S R, Skalisz L L, Beijamini V, Vital M A, Andreatini R. the antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission.  Eur Neuropsychopharmacol. 2000;  10 223-228
    PubMedGoogle Scholar
  • 44 Kalinowsky L B, Putnam T J. Attempts at treatment of schizophrenia and other nonepileptic psychoses with dilantin.  Arch Neurol Psychiatry. 1943;  49 414-420
    PubMedGoogle Scholar
  • 45 Kidron R, Averbuch I, Klein E, Belmaker R H. Carbamazepine induced reduction of blood levels of haloperidol in chronic schizophrenia.  Biol Psychiatry. 1985;  20 199-228
    CrossrefPubMedGoogle Scholar
  • 46 Klein E, Bental E, Lerer B, Belmaker H. Carbamazepine and haloperidol vs. placebo and haloperidol in excited psychoses.  Arch Gen Psychiatry. 1984;  41 165-170
    PubMedGoogle Scholar
  • 47 Klitgaard N A, Kristensen O. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients.  Eur J Clin Pharmacol. 1986;  31 91-94
    CrossrefPubMedGoogle Scholar
  • 48 Klosterskov-Jensen P, Saano V, Haring P, Svenstrup B, Menge G P. Possible interaction between oxcarbazepine and an oral contraceptive.  Epilepsia. 1992;  33 1149-1152
    PubMedGoogle Scholar
  • 49 Krämer G. Oxcarbazepin (Trileptal®): Ein neues Antiepileptikum zur Mono- und Kombinationstherapie.  Akt Neurologie. 2000;  27 59-71
    PubMedGoogle Scholar
  • 50 Krämer G, Bülau P, Blankenhorn V, Stoll K D. Oxcarbazepin und Carbamazepin. Kinetik, Metabolismus, Enzyminduktion und Konsequenzen für den klinischen Einsatz.  Münch Med Wschr. 1990;  132 (1) S71-S74
    PubMedGoogle Scholar
  • 51 Krämer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers.  Epilepsia. 1991;  32 (1) 70
    PubMedGoogle Scholar
  • 52 Kristensen O, Klitgaard N A, Jönsson B, Sindrup S. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations.  Acta Neurol Scand. 1983;  68 145-150
    CrossrefPubMedGoogle Scholar
  • 53 Lambert P A, Carraz G, Borselli S, Carrel S. Action neuropsychotrope d'un nouvel antiépileptique: Le Dépamide.  Ann Med Psychol. 1966;  1 707-710
    PubMedGoogle Scholar
  • 54 Lambert P A, Carraz G, Borselli S, Bouchardy M. Le dipropyl-acetamide dans le traitement de la psychose maniaco-depressive.  L'Encephale. 1975;  1 25-31
    PubMedGoogle Scholar
  • 55 Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases.  Pharmacopsychiatry. 1996;  29 156-158
    PubMedGoogle Scholar
  • 56 Litten R Z, Allen J P. Pharmacological therapies of alcohol addiction. In: Miller NS, Gold MS (eds) Pharmacological therapies in drug and alcohol disorders. New York; Marcel Dekker 1994: 127-141
    Google Scholar
  • 57 Lorr M, Klett C, McNair D M, Lasky J J. Inpatient Multidimensional Psychiatric Scale. Palo Alto/CA; Consulting Psychologists Press 1962
  • 58 Macdonald R L, Kelly K M. Antiepileptic drug mechanism of action.  Epilepsia. 1995;  36 (2) S2-12
    PubMedGoogle Scholar
  • 59 McElroy S L, Pope H G, Keck P E, et al. Treatment of psychiatric disorders with valproate: a series of 73 cases.  Psychiatrie & Psychobiologie. 1988;  3 81-85
    PubMedGoogle Scholar
  • 60 McElroy S L, Keck P E, Pope H G, et al. Valproate in the treatment of bipolar disorders: literature review and clinical guidelines.  J Clin Psychopharmacol. 1992;  12 42S-52S
    PubMedGoogle Scholar
  • 61 Monroe R R. Limbic ictus and atypical psychoses.  J Nerv Ment Dis. 1982;  170 711-716
    PubMedGoogle Scholar
  • 62 Müller A A, Stoll K D. Carbamazepine and oxcarbazepine in the treatment of manic syndrome - Studies in Germany. In: Emrich H, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam; Elsevier 1984: 139-147
    Google Scholar
  • 63 Müller-Oerlinghausen B, Grof P, Schou M. Lithium and suicide prevention.  Br J Psychiatry. 1999;  175 90-91
    PubMedGoogle Scholar
  • 64 Müller-Oerlinghausen B, Retzow A, Henn F A, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group.  J Clin Psychopharmacol. 2000;  20 195-203
    CrossrefPubMedGoogle Scholar
  • 65 Neppe V M. Carbamazepine as adjunctive treatment in nonepileptic chronic inpatients with EEG temporal lobe abnormalities.  J Clin Psychiatry. 1983;  44 236-331
    PubMedGoogle Scholar
  • 66 Nielsen O A, Johannessen A C, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study.  Epilepsy Res. 1988;  2 269-271
    CrossrefPubMedGoogle Scholar
  • 67 Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A, Matsushita T, Naklao T, Ogura C. Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report.  Folia Psychiatr Neurol Jpan. 1973;  27 617-630
    PubMedGoogle Scholar
  • 68 Okuma T, Inanaga K, Otsuki S, Sarai K. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study.  Psychopharmacology. 1979;  66 211-217
    CrossrefPubMedGoogle Scholar
  • 69 Pendlebury S C, Moses D K, Eadie M J. Hyponatremia during oxcarbazepine therapy.  Hum Toxicol. 1989;  8 337-344
    PubMedGoogle Scholar
  • 70 Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, Di Perri R. Effect of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy.  Acta Neurol Scand. 1994;  90 130-132
    PubMedGoogle Scholar
  • 71 Post R M, Uhde T W, Putnam F W, Ballenger J C, Berrettini W H. Kindling and carbamazepine in affective illness.  J Nerv Ment Dis. 1982;  170 717-731
    PubMedGoogle Scholar
  • 72 Post R M, Denicoff K D, Frye M A, Dunn R T, Leverich G S, Osuch E, Speer A. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th Century.  Neuropsychobiology. 1998;  38 152-166
    PubMedGoogle Scholar
  • 73 Puzy¿nski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders.  J Affect Disord. 1984;  6 116-121
    PubMedGoogle Scholar
  • 74 Raptis C, Garacia-Borreguero D, Weber M M, Dose M, Bremer D, Emrich H M. Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide.  Acta Psychiatr Scand. 1990;  81 (2) 162-167
    PubMedGoogle Scholar
  • 75 Reinikainen K J, Keränen T, Halonen T, Komulainen H, Riekkinnen P J. Comparison of oxcarbazepine and carbamazepine: a double-blind study.  Epilepsy Res. 1987;  1 284-289
    CrossrefPubMedGoogle Scholar
  • 76 Ritola E, Malinen L. A double blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome.  Acta Psychiatr Scand. 1981;  64 254-259
    CrossrefPubMedGoogle Scholar
  • 77 Schachter S C. Oxcarbazepine: current status and clinical applications.  Experimental Opinions of Investigative Drugs. 1999;  8 1-10
    PubMedGoogle Scholar
  • 78 Schachter S. The next wave of anticonvulsants - Focus on levetiracetam, oxcarbazepine and zonisamide.  CNS Drugs. 2000;  14 (3) 229-249
    PubMedGoogle Scholar
  • 79 Sindrup S H, Brosen K, Hansen M GJ, Aaes-Jorgensen T, Overb K F. Pharmacokinetics of citalopram in relation to the sparteine and mephenytoin oxidation polymorphism.  Ther Drug Monit. 1993;  15 11-17
    PubMedGoogle Scholar
  • 80 Steinhoff B J, Stoll K-D, Stodieck S RG, et al. Hyponatremic coma under oxcarbazepine therapy.  Epilepsy Res. 1992;  11 67-70
    CrossrefPubMedGoogle Scholar
  • 81 Takezaki I I, Hanaoka M. The use of carbamazepine in the control of manic depressive states.  J Clin Psychiatry. 1971;  13 173-182
    PubMedGoogle Scholar
  • 82 Tecoma E S. Oxcarbazepine.  Epilepsia. 1999;  40 (5) S37-S46
    PubMedGoogle Scholar
  • 83 Theisohn M, Heimann G. Dispositions of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers.  Eur J Clin Pharmacol. 1982;  22 545-551
    PubMedGoogle Scholar
  • 84 Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial.  Pharmacopsychiatry. 1996;  29 103-107
    Google Scholar
  • 85 Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics.  Pharmacopsychiatry. 1995;  28 26-28
    PubMedGoogle Scholar
  • 86 van Amelsvoort T, Bakshi R, Devaux C B, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.  Epilepsia. 1994;  35 (1) 181-188
    PubMedGoogle Scholar
  • 87 van Heiningen P NM, Eve M D, Oosterhuis B, Jonkman J HG, de Bruin H, Hulsman J A, Richens A, Jensen P K. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine.  Clin Pharmacol Ther. 1991;  50 410-419
    PubMedGoogle Scholar
  • 88 Velikonja M, Heinrich K. Effect of oxcarbazepine (GP 47.680) on affective and schizoaffective symptoms: A preliminary report. In: Emrich H, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam; Elsevier 1984: 208-210
    Google Scholar
  • 89 Vencovsky¿ E, Soucek K, Kabes J. Prophylactic effect of dipropylacetamide in patients with bipolar affective disorders. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam; Exerpta Medica 1984: 66-67
    Google Scholar
  • 90 Wildgrube C. Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders.  Inc Clin Psychopharmacol. 1990;  5 89-94
    PubMedGoogle Scholar
  • 91 Zaccara G, Gangemi P F, Bendoni L, Menge G P, Monza G C. Evaluation of the influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.  Epilepsia. 1991;  32 (1) 71
    PubMedGoogle Scholar

Detlef E. DietrichM.D. 

Department of Clinical Psychiatry and Psychotherapy
OE 7110
Medical School Hannover

30623 Hannover
Germany

Phone: + 49-511-5326749

Fax: + 49-511-5322415

Email: dietrich.detlef@mh-hannover.de

      >